Employer wellness plans get a bad rap because employees don’t make use of them. Keas is betting that the lack of ease in accessing these programs is a big contributor. Yet self-insured employers are pouring money into these programs with the idea that they will help keep healthcare costs down or at least prevent them […]
Employer wellness plan Keas, which brings together a social network with personal health challenges, has raised more than $7.4 million. Employers’ interest in adopting wellness plans to encourage cost savings to improve their bottom lines has been growing. The digital health company’s fundraising move was listed in a Form D filing with the SEC this […]
Take a look at the most read stories on MedCity News in February. You may have missed news on startups, medical stocks and new medical devices.
Companies are increasingly turning to startups in the employer wellness space. They view them as helping staff to take a greater interest in managing their health and help employers pare down healthcare costs. Although gaming and challenges have been increasingly popular buzzwords with these programs, a frequent problem is it can be tough to hold […]
With a fresh round of investment, new clients and new hires, Keas is moving even closer to world domination of corporate wellness thanks to a social focus instead of the standard, boring portal approach. Two existing investors, Ignition Partners and Atlas Venture, are putting $8 million more into the company. It sounds like the investors […]
Corporate wellness programs have become a cause celebre of the cost-saving era in healthcare. Everyone has started using employee wellness plans and there are plenty of ways to try them. But there’s one catch: few corporate wellness solutions are saving money. “We probably shouldn’t think of wellness programs as cost-savers, at least not in the […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
